10-Q: Bausch + Lomb Reports Strong Q2 2026 Results

Bausch + Lomb Corporation announced a significant increase in revenues and operating income for the second quarter of 2026, driven by strong performance across its Vision Care, Pharmaceuticals, and Surgical segments.

Summary

• Bausch + Lomb Corporation reported revenues of $1.394 billion for the three months ended June 30, 2026, a 9% increase compared to $1.278 billion in the same period of 2025.
• For the six months ended June 30, 2026, revenues increased by 9% to $2.638 billion from $2.415 billion in the prior year.
• Operating income for the second quarter of 2026 was $83 million, a substantial improvement from an operating loss of $11 million in the second quarter of 2025.
• Net loss attributable to Bausch + Lomb Corporation narrowed to $14 million for the three months ended June 30, 2026, from $62 million in the prior year period.
• The company's Vision Care segment saw a 4% revenue increase, Pharmaceuticals segment revenue grew by 15%, and the Surgical segment revenue increased by 19% year-over-year for the quarter.
• The company ended the quarter with $367 million in cash and cash equivalents.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and a significant improvement in profitability, although a net loss was still reported.

Positives

• Revenues increased by 9% to $1.394 billion for the three months ended June 30, 2026, driven by increased pricing and volumes across segments.
• Pharmaceuticals segment revenue saw a strong 15% increase, driven by branded pharmaceuticals like MIEBO and XIIDRA.
• Surgical segment revenue grew by 19%, attributed to premium IOLs and acquisitions.
• Operating income improved significantly to $83 million from a loss of $11 million in the prior year's quarter.
• Net loss narrowed to $14 million from $62 million in the prior year's quarter.
• Cost of goods sold as a percentage of product sales improved to 37.9% from 41.1% due to favorable product mix.
• The company ended the period with $378 million in cash and cash equivalents and restricted cash.

Negatives

• Net loss attributable to Bausch + Lomb Corporation was $14 million for the three months ended June 30, 2026.
• The company reported a net loss of $85 million for the six months ended June 30, 2026.
• The provision for income taxes increased significantly to $1 million for the three months ended June 30, 2026, from a benefit of $89 million in the prior year period.
• The company's Vision Care segment's revenue growth was a more modest 4% compared to Pharmaceuticals and Surgical segments.

Risks

• Adverse economic conditions, including inflation and interest rates, could negatively impact revenues and margins.
• Tariffs, trade policies, and global supply chain disruptions pose risks to manufacturing and distribution costs.
• The company faces challenges managing an independent business post-IPO, including limited transitional services from BHC.
• Potential conflicts of interest may arise due to shared directors and officers with Bausch Health Companies Inc. (BHC).
• The proposed separation from BHC carries risks related to expected benefits, costs, timing, and potential business disruptions.
• Ongoing or future litigation, claims, and regulatory investigations could result in significant costs and liabilities.
• Changes in healthcare legislation and policy could lead to pricing restrictions and negatively impact business.
• The introduction of generic or biosimilar competitors could significantly decrease product sales.

Future Outlook

The company anticipates continued growth driven by its product pipeline, including new formulations and product launches in Vision Care, Pharmaceuticals, and Surgical segments. Specific product developments like Lumify NXT, Blink NutriTears, and enVista Aspire/Envy are highlighted as growth drivers. The company expects to remain in compliance with its financial covenants and meet its debt service obligations.

Management Comments

• The company's mission is simple, yet powerful: helping you see better, to live better.
• Bausch + Lomb has a comprehensive portfolio of approximately 400 products, positioning it to compete in all areas of the eye health market.
• The company believes it has a significant innovation opportunity today with a robust global pipeline.

Industry Context

StockSavvy.ai notes that Bausch + Lomb's performance reflects a broader trend in the eye health sector, with strong demand for both vision correction products (contact lenses, IOLs) and pharmaceutical treatments for eye conditions. The company's diversified segment approach allows it to capitalize on growth across these sub-sectors.

Legal Proceedings

• Bausch + Lomb Corporation is no longer a party to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation.
• Johnson & Johnson continues to have indemnification obligations for Shower to Shower product liability litigation.
• A jury awarded a monetary judgment in favor of Doctors Allergy in a breach of contract lawsuit; a motion for judgment notwithstanding the verdict is pending.
• Settlement reached with DRL in Lumify patent litigation, with a market entry date of June 30, 2027, for DRL's generic drops.

Related Party Transactions

• Amounts payable to BHC and its affiliates were $7 million as of June 30, 2026.
• Amounts due from BHC and its affiliates were $8 million as of June 30, 2026.
• Transition Services Agreement with BHC for administrative, HR, treasury, and support services has largely expired.

Stakeholder Impact

• Shareholders may see positive impacts from improved financial performance and revenue growth.
• Employees may benefit from the company's focus on innovation and growth, though restructuring costs were noted.
• Customers are likely to benefit from continued product development and potential new offerings in eye care.
• Creditors are assured by the company's compliance with debt covenants and expected ability to meet obligations.

Next Steps

• Continue to monitor the FDA's response regarding the re-inspection of the Tampa facility.
• Advance pipeline products, including Lumify NXT, Dual-Action Lifitegrast, and enVista Beyond.
• Evaluate the impact of global tax reforms and geopolitical events on operations.
• Continue to manage debt obligations and covenants.

Key Dates

Recommendation

The company shows strong revenue growth and improved profitability, but still reported a net loss. The ongoing separation from BHC and various legal proceedings introduce uncertainty, warranting a 'hold' recommendation until these factors are resolved and sustained profitability is demonstrated.

Keywords

Bausch + Lomb, Eye Health, Vision Care, Pharmaceuticals, Surgical, Contact Lenses, IOLs, Quarterly Report